Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R940343 · 1 trial · 1 indication
Change from baseline in pre-BD FEV1 (% predicted) at Week 8.
| Arm | Type | Description |
|---|---|---|
| R940343 2mg, 2 puffs bid | ACTIVE_COMPARATOR | R343 2mg, 2 puffs bid |
| Placebo | PLACEBO_COMPARATOR | - |
| R940343 1mg, 1 puff bid | ACTIVE_COMPARATOR | R343 1mg, 1 puff bid |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | 1 puff bid or 2 puffs bid |
| R940343 1mg | DRUG | R343 1mg, 1 puff bid |
| R940343 2mg | DRUG | R343 2mg, 2 puffs bid |
Inclusion Criteria: * Clinical history of asthma * Ability to perform spirometry Exclusion Criteria: * Chronic obstructive pulmonary disease or bronchiectasis * Upper or lower respiratory infection
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
R940343 is an inhaled small molecule developed by Rigel Pharmaceuticals, Inc. (ticker RIGL) as a potential treatment for asthma. It has been studied in a Phase 2 clinical trial in patients with mild to moderate asthma. R940343 is an investigational drug and is not approved for any indication.
R940343 was studied for the treatment of mild to moderate asthma. The Phase 2 trial enrolled 301 patients aged 18 years and older in the United States and Canada. R940343 remains investigational and is not approved for the treatment of asthma or any other condition.
R940343 is developed by Rigel Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol RIGL. Rigel is the sponsor of the clinical program evaluating inhaled R940343 in patients with mild to moderate asthma.
R940343 has completed a Phase 2 clinical trial in patients with mild to moderate asthma. The trial was randomized, double blind, and placebo controlled, and enrolled 301 patients. R940343 is an investigational drug and has not been approved by the FDA.
R940343 has been evaluated in one completed Phase 2 trial, NCT01591044, titled A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma. The randomized, double blind, placebo controlled study enrolled 301 patients in the United States and Canada.